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Silver is used widely in wound dressings and medical devices as a broad-spectrum antibiotic. Metallic silver and most inorganic
silver compounds ionise in moisture, body ﬂuids, and secretions to release biologically active Ag
+. The ion is absorbed into the
systemic circulation from the diet and drinking water, by inhalation and through intraparenteral administration. Percutaneous
absorption of Ag
+ through intact or damaged skin is low. Ag
+ binds strongly to metallothionein, albumins, and macroglobulins
and is metabolised to all tissues other than the brain and the central nervous system. Silver sulphide or silver selenide precipitates,
bound lysosomally in soft tissues, are inert and not associated with an irreversible toxic change. Argyria and argyrosis are the
principleeﬀectsassociatedwithheavydepositionofinsolublesilverprecipitatesinthedermisandcornea/conjunctiva.Whilstthese
changes may be profoundly disﬁguring and persistent, they are not associated with pathological damage in any tissue. The present
paper discusses the mechanisms of absorption and metabolism of silver in the human body, presumed mechanisms of argyria and
argyrosis, and the elimination of silver-protein complexes in the bile and urine. Minimum blood silver levels consistent with early
signs of argyria or argyrosis are not known. Silver allergy does occur but the extent of the problem is not known. Reference values
for silver exposure are discussed.
1.Introduction
Silver is a white lustrous transitional metallic element found
widely in the human environment. Low concentrations of
silver are present in the human body through inhalation of
particles in the air and contamination of the diet and drink-
ing water, but silver serves no trace metal value in the human
body. Increasing use of silver as an eﬃcacious chemother-
apeutic antibacterial and antifungal agent in wound care
products, medical devices (bone cements, catheters, surgi-
cal sutures, cardiovascular prostheses, and dental ﬁllings),
textiles, cosmetics, and even domestic appliances in recent
years has lead to concern as to the safety aspects of the
metal and potential risks associated with the absorption of
the biologically active Ag+ into the human body [1]. Safety
thresholds set by regulatory authorities including the World
Health Organisation and U.S. Environmental Protection
Agency are based mostly on scientiﬁc reports conducted
beforetheintroductionofthehighstandardsofexperimental
and investigative procedures and tissue analysis expected
nowadays and fail to recognise more recent work [2, 3].
Metallic silver is inert in the presence of human tissues
but ionises in the presence of moisture, body ﬂuids, and
secretions to release the biologically active Ag+ which shows
as t r o n ga ﬃnity for sulphydryl groups and other anionic
ligands of proteins, cell membranes, and tissue debris [4].
Ionisationofmetallicsilverisproportionaltothesurfacearea
of particles; release of Ag+ from nanocrystalline particles of
<20nm being more than one-hundred-fold higher than that
from silver foil or other metallic silver forms. Comparative
studies have shown that nanocrystalline silver with higher
solubility in water exhibits a sixfold or higher log reduction
in Pseudomonas aeruginosa in culture [4]. Ag+ binds protein
residues on cell membranes of sensitive bacteria, fungi,
and protozoa and is absorbed intracellularly by pinocytosis.
Subsequent denaturation and inactivation of proteins and
essential enzymes including RNA- and DNA-ases forms the
basis of the genetically regulated antimicrobial action of2 Advances in Pharmacological Sciences
silver [5, 6]. Silver-sensitive strains of bacteria and fungi
have been shown to absorb and concentrate Ag+ from dilute
solutions (1ppm) by an oligodynamic action, ﬁrst described
by the Swiss botanist Von N¨ ageli in 1893 [7]. Experimental
studies suggest that concentrations of 60ppm Ag+ should
be suﬃcient to control the majority of bacterial and fungal
pathogens [4].
Recent advances in the biotechnology of medical devices
and the ability to impregnate or coat alginates, polyurethane,
silicones, and textile ﬁbres with ionisable silver compounds
now provide clinicians with eﬃcacious means of overcoming
infections in wound care and device-related infections which
have proved costly in terms of hospital care and patient stress
as well as being a major cause for fatalities [8–10]. Wound
dressings, catheters, bone cements, dental devices, hygiene
textiles, consumer products, and other products area treated
with silver as antibiotic or preservative release bioactive
Ag+ to achieve antibacterial or antifungal action. Limited
evidence is available currently to show that nanoparticulate
silver is an eﬃcacious antiviral agent [11, 12]. Lara et
al. have shown that silver nanoparticles exert antiviral
action against HIV-1 at noncytotoxic concentrations, but
these mechanisms of action which have not been fully
elucidated involve virion binding, inhibition of replication,
and inactivation [11].
Silver should be classiﬁed as a xenobiotic metal in the
human body. Available evidence suggests that much of the
ion released precipitates with chloride or phosphate anions
or becomes strongly bound in the form of inert complexes
withalbuminsormacroglobulins;somebindsorisdeposited
in tissue debris [13, 14]. This bound ion is not available for
antibiotic purposes but is of potential signiﬁcance as a toxic
factor [4, 15].
Clinical studies with antibiotic wound dressings have
shown that most of the Ag+ released into the wound bed is
deposited superﬁcially and that minimal levels are available
for absorption [16]. Proteins in the systemic circulation
and at sites of contact avidly bind the lower concentrations
of Ag+ released from antibiotic in in-dwelling catheters,
cardiovascular devices, and orthopaedic cements, pins, and
ﬁxation materials. Occupational health studies demonstrate
that greatest risk of silver absorption is anticipated following
chronic exposures to silver and silver oxide dusts or silver
nitrate particles or aerosol droplets, each of which has been
associated with deposition of inert silver sulphide or silver
selenide precipitates in the form of argyria and argyrosis
in the skin (dermis) and eye (cornea and conjunctiva),
respectively [17, 18] .A r g y r i am a yp r e s e n ta sap r o f o u n d
cosmetic disﬁgurement which is not readily removed by
surgical (dermabrasion) or chemical means [19], but it is
notassociatedwithtissuedamageordysfunction.Long-term
usage of unregulated and medically unsupervised colloidal
silver formulations marketed as nasal decongestants, thera-
pies for allergic rhinitis, and other complaints of infective
and noninfectious aetiology are well documented causes of
argyria [19–21].
The anti-inﬂammatory eﬀects of silver nitrate or
nanocrystallinesilverhavebeenrecognisedexperimentallyin
wound care, treatment of allergic contact dermatitis ulcer-
ative colitis, and cystitis [22–26]. In dinitrochlorobenzene-
induced porcine or murine skin decreased inﬂammation
following application of nanocrystalline silver was associated
with lymphocyte apoptosis, decreased expression of pro-
inﬂammatory cytokines, and reduced gelatinase activity.
Silvernitrate(0.5%)evokedawiderlevelofcellularapoptosis
but delayed wound healing. In a rat model of ulcera-
tive colitis, administration of 4mg·kg−1 nanocrystalline
silver intracolonically or 40mg·kg−1 orally signiﬁcantly
reduced inﬂammatory changes, partly through suppression
of matrix metalloproteinase (MMP-9), tumour necrosis
factor(TNF), and interleukin-β (IL-β)a n dI L - 1 2[ 24]. Other
anti-inﬂammatory changes associated with intravesicular
administration of nanocrystalline silver in murine cystitis
included suppression of mast cells and urine histamine
levels [25].
Wright et al. examining early events in a porcine wound-
healing model noted that nanocrystalline silver in particular
as used in wound dressings was an eﬃcacious antibacterial
agent and signiﬁcantly promoted wound healing with rapid
neovascularisation and suppression of metalloproteinases
without compromising other essential events in the wound
healing cascade [26]. Further studies are now indicated to
conﬁrmthisactionofnanocrystallinesilverinhumanwound
repair.
The toxicology of silver is not well documented and
much of the available information concerning the release
of Ag+ from medical devices and other products intended
for human use is ambiguous and widely scattered. Few
relevant experimental studies in animal models are reported
openly; whilst insuﬃcient in predicting human risk from
silver exposure, they do provide relevant information on
cytotoxicity, intracellular management of Ag+,a n dr o u t e so f
excretion [1, 14, 27–29]. It is my intention here to highlight
progress on the safety assessment of silver in recent years
and to emphasise the gaps in existing knowledge relevant to
establishing realistic safety thresholds.
2. Absorption andMetabolism of Silver
Expressions of toxicity for any xenobiotic material are
related directly to the amount absorbed into the body,
its metabolism and accumulation in target organs, and
cellularvulnerabilitytoirreversibletoxicchange.Clinicaland
experimental studies have shown that metals absorbed into
the body interact and compete for binding sites on carrier
proteins, and that when protective mechanisms aﬀorded
by key metal-binding proteins like metallothioneins and
the epidermal barrier function become saturated, toxic
changes occur [30–32]. Silver is absorbed into the human
bodythroughingestion,inhalation,intraparenteralinsertion
of medical devices, and through dermal contact, but the
literature on silver absorption by all routes in humans is
fragmentary, poorly correlated, and not strong statistically.
Metabolicpathwaysaresimilarirrespectiveofrouteofuptake
[1]. Much information on the uptake of silver as a cause of
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health studies where workers have been exposed to silver
and silver compounds over many years [3, 17, 33, 34]. From
this data it is rarely possible to identify how much silver is
absorbed into the circulation from the gastrointestinal tract,
lungs, or percutaneous absorption or how much is retained,
but urinary or faecal silver excretion may be informative
[17, 35–37]. The maximum carrying capacity of human
blood for silver is not known but is expected to relate
to albumin and macroglobulin concentrations. Armitage et
al. studied the uptake of silver in the blood of workers
exposed occupationally to silver and reported levels ranging
from 0.1 to 23.0μg·L−1 with the highest levels in silver
reclaimers [38]. Few objective studies on silver uptake and
excretion are reported but Di Vincenzo et al. noted that
in 37 workers exposed to silver in smelting and reﬁning,
mean silver concentrations in blood, urine, and faeces were
11μg·L−1, <0.005μg·g−1,a n d1 5 μg·g−1,r e s p e c t i v e l y[ 17].
Hair concentrations of silver were markedly higher at 130 ±
160μg·g−1 compared to 0.57 ± 0.56μg·g−1 in controls.
2.1. Oral Administration and Gastrointestinal Absorption.
Principle routes for buccal or gastrointestinal absorption of
silver include
(i) contaminated food,
(ii) occupational exposures to metallic silver dust, silver
oxide, and silver nitrate aerosols,
(iii) drinking water (including use of silver:copper ﬁlters
in water puriﬁcation),
(iv) silver nitrate or colloidal silver therapies in oral
hygiene and gastrointestinal infection,
(v) colloidal silver preparations labelled as “food supple-
ments” or “alternative medicines”,
(vi) silver acetate antismoking therapies,
(vii) silver amalgams used in dentistry,
(viii) accidental consumption of silver nitrate or other
colourless silver compounds.
Silver absorption through buccal membranes and gastroin-
testinal mucosae is determined by the ionisation of the
silver source and availability of “free” Ag+ to interact with
protein receptors on cell membranes. Passive uptake is not
indicated on account of the high reactivity of the silver ion
and its binding capacity of sulphydryl, carboxyl, hydroxyl,
and protein ligands on mucosal surfaces and cell debris.
Biologically active Ag+ readily binds and precipitates with
organic constituents of food (phytate, ﬁbres, etc.) and
inorganiccationslikechlorideandphosphategreatly,thereby
reducing absorption. Current estimates suggest that less than
10% of the silver ingested by humans is absorbed into the
circulation [18], but this can be expected to vary widely
according to the age, health and nutritional status, and
composition of the diet.
Individual case studies like that conducted in a severely
argyric patient following silver acetate antismoking therapy
indicate that the amount of silver absorbed is low but
that 18% of this is retained in the body [39]. After 2
years self administration of an antismoking remedy, this
patient exhibited an estimated total body burden of 6.4g
silver with high levels of silver in forearm skin exposed to
solar irradiation. Her blood silver levels increased marginally
within 2 hours of administration of a radiolabelled ( 110mAg)
silver acetate lozenge, and urinary silver excretion remained
fairly constant over 7 days. Studies relating to the absorption
and metabolism of silver from dental amalgams show good
correlations between levels of silver eluting from dental
amalgams and concentrations observed in soft tissues and
in blood, hair, and urine [40, 41]. The famous “blue man”
of Barnum and Bailey’s Circus was believed to contain as
much as 90–100g of silver in his body with deposits in bone
(0.21%),muscle(0.16%),kidney(0.24%),andheart(0.15%)
but the reliability of silver quantitation in tissues in 1927 is
questioned [42].
Presently, toxic risks associated with silver ingestion
are low since most products releasing Ag+ for oral or
gastrointestinal hygiene have been removed from current
pharmacopoeias and permitted lists in most countries in
view of the risks of argyria [2, 3]. Silver is widely used
in the puriﬁcation of drinking water, and in the form of
silver copper ﬁlters, has a major role in cleansing hospital
water systems [43]. Average levels of silver in natural waters
was at 0.2μg·L−1, and levels in drinking water (USA) that
had not been treated with silver for disinfection purposes
rangedfrombarelydetectableto5μg·L−1 [44].Watertreated
with silver may have levels of 50μg·L−1, with most of this
silver present in a nondissociated form as silver chloride.
Estimates suggest that the silver absorbed from drinking
water represents a relatively low proportion to that absorbed
from the diet which ranged from 7 to 80μg daily. The World
Health Organisation considered in 1996 that on the basis of
present epidemiological and pharmacokinetic knowledge, a
lifetime intake of about 10g of silver can be considered the
human No Observable Adverse Eﬀect Level (NOAEL) and
that the contribution of silver from drinking water would
be negligible [44]. Even in special situations as when silver
is added to water for maintaining bacteriological quality,
concentrations of silver of 0.1mg·L−1 (a concentration that
gives a total dose over 70 years of 50% of the human
NOAEL of 10g) can be tolerated without risks to health
[43, 44]. Greater risks are expected through uncontrolled
use of colloidal silver products containing unspeciﬁed levels
of ionisable silver which are commercially available in some
countries as food additives, health supplements, breath
fresheners, multipurpose antiseptics, topical therapies, and
many other claims; many of which are not substantiated by
scientiﬁc or clinical evidence [45–47].
Older studies document therapeutic administration or
accidental consumption of high doses of silver nitrate as
a cause of argyria and argyrosis, corrosive damage in the
mouth or gastrointestinal tract, pain, and even fatality [48,
49]. Lethal oral concentrations of silver nitrate in humans
have been estimated at approximately 10g, but this is largely
attributable to the strong acidity of the nitrate anion released
and not Ag+ absorbed [2]. Blumberg and Carey reported a
caseofachronicallyill33-years-oldladywhohadsupposedly
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alternate periods of 2 weeks for over a year (total dose 6.4g)
and who showed greatly elevated blood silver of 0.5mg/L
(normal ca 2.3μg/L) [48]. It is unclear whether ill health
was in part due to the corrosive eﬀects of the nitrate or
to other causes but she developed generalised argyria even
though her argyraemia declined slightly after 3 months
following withdrawal of treatment. Several other cases are
reported where intentional or accidental oral consumption
of silver nitrate led to gastrointestinal lesions but where the
actual amount of silver ingested is not known [49]. The
low systemic toxicity of oral metallic silver is illustrated by
a study of 30 healthy volunteers who consumed silver leaf
(50mg/day) for 20 days [50]. Apart from transitory changes
in hepatic enzymes, the treatment was well tolerated without
symptoms of argyria.
Animal models provide limited predictive information
concerning the gastrointestinal absorption of silver. As in
humans, silver nitrate solutions are highly irritant and
potentially fatal at high doses in all species due to the
anion, but the uptake of Ag+ varies greatly. Thus rats,
mice, and monkeys given silver nitrate ( 110mAg) in drinking
water absorb less than 1% of the silver administered within
1 week whereas in dogs, up to 10% may be absorbed
[51]. From these experiments, the authors reasoned that
a 70-kg man would retain approximately 4% of the dose
administered. This extrapolation is seriously ﬂawed on
accountoftheimprecisionoftheexperimentsconductedand
wide interspecies diﬀerences in gastrointestinal physiology
and dietary requirements. Uptake and retention of silver was
based upon patterns of intake and faecal excretion patterns
but did not allow for secondary and tertiary excretion via the
urine and hair [1, 17]. Biliary excretion is the principle route
for elimination of silver from the human body.
2.2. Inhalation. Argyria and argyrosis provide unequivocal
evidenceforsilverabsorptionfollowinglong-terminhalation
of colloidal silver preparations or occupational exposures
to silver or silver oxide dusts or silver nitrate [47, 52].
Detailed study of the uptake of silver through nasal and
respiratory membranes has not been seen, but it is expected
that inhaled silver or silver compounds ionise in mucoid
secretions or alveolar pulmonary surfactants allowing Ag+
to be absorbed through alveolar epithelia. Silver precipitates
in lungs and is absorbed by alveolar macrophages, but it is
unclear to what extent Ag+ interacts with or is precipitated
by the phospholipid content of this pulmonary surfactant, or
whether this secretion acts as a barrier to absorption.
Di Vincenzo et al. evaluated 37 workers involved in silver
industries and reported blood, urine, and faecal silver levels
of 11μg·L−1, <0.005μg·g−1,a n d1 5 μg·g−1,r e s p e c t i v e l y ,
compared to <0.5μg·L−1, <0.005μg·g−1,a n d<1.5μg·g−1
in nonsilver-exposed subjects [17]. They estimated that
human exposure to the threshold limit values, set by the
AmericanConferenceofGovernmentalIndustrialHygienists
(ACGIH) and the European Union of 0.1mg/m3 could
lead to faecal excretion of 1mg of silver daily, but that
argyria is unlikely to occur at these exposure levels. Other
research demonstrates that blood silver is much inﬂuenced
by the solubility and ionisation capacity of environmental
silver exposures. Thus, Armitage et al. showed that blood
silver levels in melters, reﬁners, and silver nitrate producers
exposed to soluble silver salts were in the range from 0.1
to 23μg·L−1 whereas those exposed to metallic silver with
considerably lower ionisation potential showed argyraemias
of 0.2–2.8μg·L−1 (control <0.1μg·L−1)[ 38]. Neither group
exhibited argyria. In a similar way, 27 silver reclamation
workers exposed to airborne silver halides of low solubility
at 0.005 to 0.240mg/m3 exhibited very low absorption with
blood silver levels of 0.01μg·L−1 [53].
Occupational health reports published before the intro-
duction of stringent health and safety at work regulations
show that inhalation of silver nitrate dust is a cause
of bronchitis, squamous metaplasia, and pigmentation of
the respiratory tract resembling anthracosis and siderosis
[54]. Rosenman et al. [33, 34] examined 27 workers in a
silver plant exposed to metallic silver, silver oxide, silver
chloride, and silver alloyed with other metals and reported
that those exposed to environmental silver contamination
levels exceeding the recommended 0.01mg/m3 (i.e., 0.04–
0.35mg/m3) showed raised blood and urinary silver levels
(blood Ag, >0.27μg·100mL−1; urine Ag, >1.91μg·L−1), but
that blood or urine silver levels did not correlate well with
levels of environmental silver in work areas. A 29-years-
old man accidentally inhaled dust containing 110mAg and
65Zn in a minor nuclear reactor incident [55]. He was
assumed to have inhaled about 100nCi of each element,
the speciﬁc activities being approximately 15Ci and 3Ci per
gram respectively. Radio labelled silver was monitored in his
lungs, urine, and faeces for up to 200 days. Faecal excretion
persisted for at least 300 days. The half-life of silver in this
patient was estimated to be 52 days.
Greater occupational risk may be experienced by those
exposed to inhalation of airborne silver particles as used
in impregnation of biomaterials and in plating. As Bur-
rell demonstrated, nanocrystalline particles (<20nm diam.)
with a large surface to volume ration are expected to be
dissolved more rapidly in moisture and achieve greater
absorption [4]. This implies that increased silver dissolving
in alveolar ﬂuid will lead to greater lung volumes. Alveolar
macrophages (dust cells) sequester a large proportion of
silverparticlesinhaled,therebylimitingtheamountavailable
to dissolve in alveolar moisture or to invoke inﬂammatory
changes. Reference values have not been set on this problem
but some hygienists place the risk of nasal and pharyngeal
inﬂammationatexposuresaslowas0.1mg/m3 withparticles
of grain size <20nm diameter [56]. Much research is needed
in this area.
Extrapolation of human risk from inhalation toxicity
studiesofsilverinanimalmodelsiscomplexinviewofmajor
interspecies diﬀerences in respiratory patterns and relative
lung volumes [57]. Whereas absorption of silver in a dog’s
lung following intratracheal administration (equivalent to
1μgAg per cm2. daily) is low, rats exposed to nanoparticulate
silver exhibited a rapid clearance pattern [58]. Alveolar
macrophages were involved in mobilisation of silver released
from silver nitrate, and silver precipitates were seen in alve-
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indicated that in subacute (90 days) inhalation studies, rats
exposed to nanosilver (18nm diameter) for 6 hours daily
the lung function was markedly depressed, and female rats
exhibited a dose-related increase in inﬂammatory responses
[59]. Thickening of alveolar membranes and granulomatous
changes were reported after prolonged exposure to silver
nanoparticles, but fatalities were not recorded.
2.3. Dermal Contact and Percutaneous Absorption. The
majority of products containing silver or silver compounds
for antibiotic purposes come into contact with human
skin at some time, but clinical and experimental studies
indicate that percutaneous absorption of silver is exceedingly
low. Epidermal keratin and phospholipids of the epidermal
barrier function provide eﬀective barriers with exposed
sulphydryl groups irreversibly binding free Ag+,i nm u c h
the same way as other metallic elements [30, 60]. Where
severe generalised argyria has been reported in occupational
situations, it is expected that the greatest proportion of
the Ag+ absorbed occurs through inhalation or through
contamination of contaminated food and drinking water
[52].
The increasing use of metallic silver, silver thread, or
silver impregnates in textile ﬁbres designed for hygiene pur-
poses might be expected to lead to percutaneous absorption,
increased blood silver, and some accumulation of silver
precipitates in the skin in chronic exposures. However, risks
of argyria through the use of silver antibiotics in textiles
and hygiene clothing are negligible even where the skin is
warmandhydrated[1].Asdiscussedintherecentconference
“Biofunctional Textiles and the Skin” [61], concentrations of
Ag+ released for controlling dermatophytes and superﬁcial
bacterial infections were exceedingly low and sustained.
Whilst more clinical research is necessary in this area,
it is noteworthy that when a wound dressing containing
85mg·100cm−1 was applied to the skin of patients with
chronic ulcers for 4 weeks, blood levels of silver were not
signiﬁcantly diﬀerent from control patients [16].
Tracer studies using 111Ag indicate that <4% of the total
Ag+ released from topically applied silver nitrate solution is
absorbed through intact skin [62]. Very low but perceptible
penetration of nanoparticulate silver was demonstrated in
human skin in vitro with in Franz perfusion cells [63].
Mediansilverconcentrationsof0.46ng/cm2 and2.32ng/cm2
(range 0.43–11.6) were found in the receiving solutions of
cells where the solution of nanoparticles was applied on
intact skin and damaged skin, respectively. Granules of inert
silver precipitate were detected in the stratum corneum and
the outer layers of the epidermis by electron microscopy.
Silver ﬂux in damaged skin after 24 hours was 0.62 ±
0.2ng/cm2 with a lag phase of <1 hour. Penetration of silver
through guinea pig skin, which is similar in thickness to
human skin, was estimated to be <1% in 5 hours [64].
Clinical studies have shown that silver sulphadiazine
(100g) in an amphiphilic formulation (Flamazine) is not
noticeably absorbed through intact skin but in burned
patients (>5% total body surface) and that percutaneous
absorption increased in line with the severity of the wounds,
their depth and vascularity, and the concentration applied
[35, 65]. Patients with >20% burns exhibited blood silver
levels exceeding 200μg·L−1 with the highest concentrations
at 310μg·L−1, without argyria. Blood silver levels increased
twentyfold within 6 hours to at least 40μg/L, rising to
plateau after 4–7 days. Silver nitrate is appreciably more
astringent than silver sulphadiazine and ionises more rapidly
when applied topically as Strong Silver Nitrate (75%),
silver nitrate sticks/pencils, or douches to remove warts,
callus or undesirable granulations, but Ag+ penetration is
very low. Ag+ binds to epidermal keratin and blackens on
exposure to solar radiation to give characteristic brown-
black discoloration. Local skin discolorations rarely occur
following application of sustained silver-release wound
dressings and occupational contact with silver oxide and
other ionisable silver compounds, but are not representative
of true argyria which is long lasting. Experimental studies
have demonstrated that silver precipitates in epidermal
wound debris, proteins (albumins and macroglobulins) in
wound exudates, or as relatively insoluble silver chloride
in the skin surface exudates to be lost in normal repair
processes [13].
2.4. Miscellaneous Routes of Silver Absorption. Silver is
employed in catheters for renal drainage, central vascu-
lar insertion, intraventricular drainage in patients with
hydrocephaly and cerebrospinal ﬂuid disorders, and in in-
dwelling intraperitoneal use [8]. A sustained release of Ag+
from metallic silver, silver sulphadiazine, or other silver
compoundsisnecessarytoachieveantimicrobialeﬃcacy,but
the amount released into the circulation for binding plasma
albumins and macroglobulins is not known. Schierholz et al.
[15]consideredthatmostofthisirreversiblyboundsilverhas
no toxicological, physiological, or antimicrobial signiﬁcance
and that silver-coating or impregnation of medical devices is
only eﬀective clinically when the concentration of free Ag+ is
increased and the eﬀect of contact with serum proteins and
inorganic anions minimised.
Isolated cases are reported where abnormally high blood
or tissue silver levels hasbeen associated with the useof silver
in patients implanted with silver-containing heart valves,
bone cements, and acupuncture needles but none show
silver or Ag+-binding to be a cause of tissue damage. A
76-year-old patient implanted with total hip replacement
was shown to have blood silver 1000 times higher than
normal, but this declined rapidly following the removal of
the prosthesis and silver-containing bone cement [66, 67].
Duringthefollowing2years,herserumsilverconcentrations
decreased from >60 to 20 times higher than normal, and
the patient partially recovered from an idiopathic muscle
paralysis. A second interesting case of raised blood silver
related to the use of silver as an antibiotic or anticalciﬁcation
additive in bioprosthetic heart valves [68]. The valve was
withdrawn from clinical use for reasons other than the
silver inclusion or Ag+ release, but sheep implanted with
silvered valves exhibited transitory increases in argyraemia
to 40ppb within 10 days of implant with decline to
normal 30 days after surgery. Silver accumulated in the liver6 Advances in Pharmacological Sciences
(16.75mg·g−1 dry wt.), kidney (8mg·g−1), lung, brain, and
spleen (<5mg·g−1) without evidence of toxicity.
Silver and gold acupuncture needles used in ancient
Japanese “Hari therapy” for relief of muscular pains, fatigue,
and other discomforts are potential causes of macular or
more generalised argyria-like symptoms [69, 70]. Blood
silver levels are not known from either report but the extent
of argyria was related to the duration of acupuncture therapy
and the number of needles inserted, and hence the quantity
ofAg+ releaseddirectlyintothedermis.One57-year-oldlady
isrecordedasimplanting2,500needlesin13yearstoalleviate
symptoms of rheumatic fever.
2.5. Silver Metabolism. Silver absorbed into the body as Ag+
readily binds to intracellular proteins, notably serum albu-
mins and macroglobulins for metabolism and distribution
to bone and soft tissues. Experimental studies have demon-
strated that Ag+ actively absorbed from silver nitrate or silver
sulphadiazineinducesandbindsthecysteine-richproteins—
metallothioneins (MTs) I and II in metabolically active cells
of the wound margin [14, 71]. MTs are major metal carrier
proteins but also serve as cytoprotectants in binding toxic
metal ions thereby reducing risks of cytoplasmic damage.
Controversies exist on the predominant routes of silver
metabolism in the human body, its transitory or longer-term
accumulation in kidney, liver, and bone, and its excretion
patterns in bile, urine, hair, and nail [36, 39]. The biliary
route of excretion predominates over the urinary route but
urinary silver measurement may provide a convenient index
of silver absorption by all routes and serve as a guide to the
total silver content of the body at blood levels of <100μg·L−1
[36, 65]. At higher concentrations, patterns of urinary excre-
tion are irregular. Biological monitoring of workers exposed
to long-term environmental silver residues has shown raised
silver concentrations in hair, blood, urine, and faeces [17,
35], but faecal silver represents that excreted in bile plus
the 90% or more ingested with food and not absorbed
into the circulation. From their examination of 37 silver
workers, Di Vincenzo et al. concluded that at recommended
environmental concentrations of 0.1mg/m3 (TLV), faecal
excretion of silver would be about 1mg daily [17]. Critical
evaluation of reported clinical and experimental studies has
shown that silver is not absorbed into neurological tissue but
is bound as inert precipitates in lysosomal vacuoles of the
blood brain barrier and blood-CSF barrier [72, 73].
3. Manifestations of SilverToxicity
3.1. Argyria. Argyria is the principle manifestation of
chronic inhalation or ingestion of metallic silver or ionisable
silver compounds. Excessive absorption of Ag+ over a long
period leads to a state of silver “overload” in the circulation,
where absorption exceeds the capacity of the liver or kidney
to eliminate the metal in bile and urine, respectively. Argyria
is characterised by the deposition of inert precipitates
of silver selenide and silver sulphide in the connective
tissue surrounding the vascular tissue and glands of the
papillary layer of the dermis but not epidermis [52, 69, 70].
The ﬁne deposits are inert, intracellular (lysosomally bound)
or intercellular in distribution, and long lasting or per-
manent. The mild to profound blue-grey discolorations of
the skin and nail bed occur mainly in light-exposed areas
and on occasions may be severely disﬁguring [19]. There
is no evidence to associate argyria with cellular damage or
altered sensory perception in the skin, and even in cases of
profound discoloration, argyria is not life threatening. In
severe cases of generalised argyria, the discolorations may be
psychologicallydisturbingsincetheyarenotreadilyremoved
chemically or by surgical dermabrasion. Fatalities in patients
with profound argyria or argyrosis have been attributed to
pre-existing medical conditions and not silver-related aetiol-
ogy. Argyrosis more speciﬁcally denotes silver precipitation
in the cornea or conjunctiva of the eye and is regarded by
some as a more sensitive indicator of silver exposure [33].
Whilst argyria is an unequivocal manifestation of chronic
exposure to silver, on occasions, raised blood silver levels
(argyraemias) are reported in silver workers where overt
discoloration of the skin, eyes, mucus membranes, or nail
bed are not recognised [35, 53].
The mechanism for dermal argyria is not fully under-
stood but is thought to relate to imbalances in the local
concentrations of soluble and insoluble complexes of silver
in the middle or upper dermis and the action of lysosomal
reductase [74]. Buckley and Terhaar argued that in the mid-
dermis, insoluble silver appears to be in an equilibrium
with a variety of soluble forms of silver such as Ag+ and
silver mercaptides rich in cysteine and homocysteine, both
of which are soluble at >pH 7. They considered that an
increase in soluble silver content involves the formation of
more insoluble silver by a reductive process represented by
the equilibrium
−e
+e
Ag0 Ag+
Formation of insoluble silver precipitate in dermal granules
has been attributed to lysosomal action with the concen-
tration of silver in lysosomes estimated to be 10−5 M. They
estimated that this molar concentration is “similar to the
amount required to maintain oxidative stability of silver in
dispersions such as Argyrol (a colloidal mild silver protein)”.
They also suggested that a critical concentration of soluble
silver exists, below which any lysosomal reductase is inactive,
and where silver remains solubilised. Whilst these assertions
have not been challenged, more recent work implicates
selenium as a central factor in the production of insoluble
silver complexes in argyric states. Microanalytical studies
have revealed a tenfold increase in selenium in skin biopsies
of argyric patients and have implicated the element in the
“detoxiﬁcation” of silver [75]. X-ray emission spectroscopy
of inert silver deposits in the kidney of a patient with
generalised argyria showed that the particles were composed
of silver selenide (Ag2Se) and not silver sulphide, suggesting
that selenium was replacing the sulphide moiety [76, 77].
Silverselenideisahighlyinsolublenontoxicmaterialandnot
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Despite electron microscopic evidence to the contrary
[74,78],silverdepositedinconnectivetissuearoundhairfol-
licles, and sebaceous or eccrine glands do not migrate across
the dermoepidermal interface to be excreted in desquamated
keratinocytes or in glandular secretions [52]. Small amounts
of silver sulphide deposited intercellularly in the dermis can
be expected to be phagocytosed by dermal macrophages or
eliminated through normal tissue repair process [79, 80],
but in cases of generalised argyria the discolorations of the
skin, buccal membranes, and hair and nail bed are expected
to be long lasting or permanent. Whereas blood silver levels
are usually greatly elevated in clinical argyria, argyraemia
is not a reliable guide. Thus, Coombs et al. showed that
patients treated with silver sulphadiazine for severe burns
and showing blood silver of >300μg·L−1 failed to show skin
discoloration [65] whereas other cases of overt argyria failed
to show correlation with elevated blood silver [81].
Melanin granules in the skin may protect against
argyria by absorbing solar energy, but silver is not known
to inﬂuence either melanocyte function or melanogenesis
[52]. On rare occasions where argyric discolorations have
been erroneously identiﬁed as melanoma-like lesions, silver
sulphide (or silver selenide) deposits were attributable to
Ag+ leaching from silver sutures used earlier in eye surgery
[82, 83].
3.2. Argyrosis (Argyrosis Conjunctivae). A r g y r o s i si sd e ﬁ n e d
as a dusky grey/blue pigmentation of the cornea and con-
junctiva resulting from deposition of inert silver precipitates
followingchronicoccupational,therapeutic,orenvironmen-
tal exposure to silver or soluble silver salts [33, 81, 84]. It is
frequently a more sensitive outward sign of silver exposure
than argyria, but like argyria it is not associated with
pathological damage in any tissue. Therapeutic argyroses
may have been known since the 17th Century when silver
nitrate was used to treat epilepsy and venereal diseases and
in the late 19th century when Cred´ e et al. introduced silver
nitrate as a prophylactic for neonatal eye disease [85], but
more recent reports relate more to chronic occupational
exposures to silver or the use of colloidal silver preparations
f o ro c u l a ri n f e c t i o n s[ 81, 84, 86, 87]. Exposure to silver in
soldering, in particular, is held to be a common cause of
argyrosis, but less commonly the use of silver in eyelash
tints, jewellery work, therapeutic use of silver nitrate or
colloidal silver preparations (notably 1% Argyrol, mild
silver protein in eye drops), and industrial accidents are
reported [88–93]. In each case, silver precipitates in the
form of sulphide or selenide have been reported in the
cornea, conjunctiva, lens, and lachrymal tissues with the
severity reﬂecting the duration and severity of exposure, the
ionisation of the silver compounds involved, and the nature
of the exposure. The occupational risks of argyrosis and the
toxicophysiological signiﬁcance of the cytological changes
are well illustrated in a study of 30 workers in silver nitrate
and silver oxide manufacture [33, 81]. The conjunctiva was
most frequently involved (20/30) with corneal pigmentation
in 15 workers following a mean exposure period of 5 years.
Slit lamp and visual acuity tests revealed more profound
pigmentation of the caruncle and semilunar folds of the
conjunctiva, and with corneal changes aﬀecting the limbus,
Descemet’s membrane and peripheral cornea. Lens changes
were noted in 4 patients. Electrophysiological tests revealed
a lack of retinal damage in all volunteers, but 10 reported
decreased night vision and a signiﬁcant association between
this nyctalopia and pigmentation of the conjunctiva/cornea.
Cauterisation using lunar caustic and the use of silver nitrate
to stem haemorrhages have been associated with corrosive
damage and corneal opacities mainly attributable to the
caustic action of the nitrate anion [92, 94]. On occasions,
discolorations attributable to silver precipitates in conjunc-
tiva, cornea, or lachrymal gland tissues have simulated
melanoma, but correct diagnoses have been provided by
biopsy examination and records of patients’ clinical histories
[82, 83, 95].
Correct diagnosis of argyrosis has been aided by confocal
and specular microscopy, X-ray analysis, and electron-
microscopy, but the deposition of silver precipitates in vari-
ous circumstances has varied greatly according to the type of
exposureandtheionisationpatternsofthesilvercompounds
implicated. In a study simulating Cred´ e ’ sp r e v e n t i v et h e r a p y
with 1% silver nitrate therapy for neonatal eye infections
(ophthalmia neonatorum), a lamellar keratectomy from a
very young treated child revealed electron dense granules
100–300nm in diameter deep in the corneal stroma [96]. In
contrast, in an accident victim exposed to silver nitrate in an
explosion, silver precipitates were more widely distributed in
the eyelids, conjunctiva, and superﬁcial layers of the cornea
with diﬀuse particles located in the epithelial basement
membrane, Bowman’s layer, and Descemet’s membrane
[90]. Silver-rich particles in the deep corneal stroma were
lysosomally bound in connective tissues or free within
intercellular spaces and associated with tissue debris, similar
to those reported in silver-related dermal injuries. The
mechanism of argyrosis has not been investigated in detail,
but it is expected to follow a similar pattern to that in argyria
[86, 87]. High-selenium and silver-intracellular precipitates
were prominent in the region of the rough endoplasmic
reticulum as demonstrated using X-ray microanalysis with
energy dispersive technology (EDAX) [86].
3.3. Silver in Soft Tissues. The skin (and its appendages),
eye, brain, liver, kidney spleen, and bone marrow are listed
as principle target tissues for silver deposition following
systemic absorption [3, 17, 21, 33, 42]. Critical analysis of
published literature revealed that despite claims of neurolog-
ical damage in clinical and experimental studies, silver is not
absorbed into the brain and central or peripheral nervous
systems, and there is no substantive evidence that it passes
across either the blood brain barrier or blood-CSF barrier
in any species [72, 73]. Silver acetate when used as deterrent
to smoking evokes a bitter taste in the presence of tobacco
smoke but is otherwise safe and eﬀective [39]. Elsewhere,
WesthofenandSchafer[79]presentedacaseofapatientwith
generalised argyrosis associated with progressive taste and
smell disorders, vertigo, and hypesthesia. The ﬁndings were
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hypogeusia and hyposomia were checked using subjective
and olfactory tests but apart from electron-dense deposits
of silver sulphide in macrophages and along perineuria and
nerve tracts no histological damage was recorded using light
or electron microscopy.
Clinicalandexperimentalstudiesregularlylisttheliveras
the principle organ for silver accumulation and elimination,
but apart from transitory changes in certain metabolising
enzymes, no evidence is seen to show that even in patients
with blood silver of >200μg·L−1 or advanced argyria, silver
is a cause of irreversible pathological hepatic damage [65,
97, 98]. Daily administration of 50mg silver leaf to 30
healthy volunteers for 20 days led to transitory increases
in blood phospholipid, triglycerides, cholesterol, glycaemia,
and associated enzymes, but no functional changes in
the tissue [50]. Electron microscopy has conﬁrmed that
in patients with high hepatocellular silver deposition (up
to14μg.−1 wet weight), the precipitates are inert, lysosomally
bound, and presumably extruded into bile ducts as a normal
physiological process [65, 99]. Experimental studies in ani-
mal models have shown variations in hepatic management
and biliary excretion of silver. Intravenous injection of dilute
silver nitrate was associated with biliary excretion patterns
of 0.25μg·kg−1/min. in rats, 0.05μg·kg−1/min. in rabbits,
and 0.005μg/.kg−1/min. in dogs [100]. As in other tissues,
Ag+ evokes and binds MT-1 and MT-2 and is eliminated
innocuously in bile without morphological change [101].
Subacute (28 day) toxicity tests showed that rats toler-
ated massive doses of 1000mg·kg−1 nanoparticulate silver
(60mn) without signiﬁcant changes in body weight, but that
at doses of >300mg·kg−1, increased alkaline phosphatase
and cholesterol levels may reﬂect functional liver changes
in the tissue [102]. Klaassen conﬁrmed that faecal excretion
is greatly superior to biliary elimination for silver and that
in 110mAg-labelling experiments, bile concentrations within
2 hours of intravenous administration were 16–20 times
higher than in plasma, reﬂecting clear dose-related plasma
to bile gradients [103]. Faecal excretion accounted for 70%
of the administered dose compared to <1% in urine. The
study also emphasised marked interspecies diﬀerences in
silver metabolism and excretion, with rabbits excreting the
metal at a tenth of the rate seen in rats and dogs at one
hundredth of the rate. Experimental studies in rats have
alsodemonstratedthatcopperandtheantioxidantsselenium
and vitamin E can inﬂuence the hepatobiliary transport and
retention of silver in the liver [104–106]. Copper and silver
are known to interact in MT and caeruloplasmin binding
whereas selenium exhibits a strong tendency to precipitate
silver as silver selenide, thereby promoting silver retention in
the tissue [105].
Urinary excretion of silver is appreciably lower than
biliary elimination and provides a less accurate measure
of silver absorption by all routes. Clinical studies in burn-
wound patients treated chronically with silver sulphadiazine
suggest that a “threshold” of about 100μg·L−1 blood silver
exists and that above this level urinary secretion is variable
[36, 65]. In a severely argyric patient, 18% of an oral dose
of 110mAg was retained in the body for up to 30 weeks [39].
The argyraemia in this patient 2 hours after treatment was
low (4.5 × 10−4% of the dose administered), and a small
proportion of the original dose was excreted in urine over
the next 7 days. Neither study provided evidence of renal
damage or functional impairment in a total of 23 patients
subjected to known concentrations of silver. In contrast,
mild increases in renal N-acetyl-B,D -glucosaminidase were
reported in 4 of 27 workers exposed to silver occupationally,
but the signiﬁcance of this change is unclear [34]. Other
occupational health studies conﬁrm renal management and
excretion of silver with no obvious pathological eﬀects
[17, 33, 34, 53].
Renal pathology is an expected risk where silver nitrate
is instilled into the renal pelvis or ureter as a therapy
for ﬁlarial worm infestations like Wuchereriay brancrofti
(chyluria), which represent major health risk in Southeast
Asian countries [107–109]. Renal and hepatic failure, acute
necrotizingureteritis,obstructivenephropathy,andpapillary
necrosis have been reported following injection of up to
3% silver nitrate, although practitioners consider that the
therapy is a “safe and minimally invasive treatment” for
chyluria [107, 110].
The low nephrotoxicity of silver in the urinary tract has
been conﬁrmed in experimental studies in rodents given
silver nitrate intravenously or in drinking water [111]. Silver
precipitates have been observed on glomerular basement
membranes, arteriolar endothelia and elastic laminae, with-
out obvious structural damage [112, 113]. Berry et al. noted
high levels of renal selenium sulphur and silver in the
precipitates in renal membranes and interpreted the role
of selenium as a cytoprotective agent [111]. As in human
studies, precipitates of silver sulphide or silver selenide were
lysosomally bound. Renal toxicity was not recorded in mice
given high doses of 65mg·kg−1 silver nitrate daily for up to
14 weeks [100].
Theabilityofsilversulphadiazine(SSD)andsilvernitrate
to evoke changes in white blood cell populations (WBC)
following therapy in burn wounds is equivocal [114, 115].
Since its introduction in 1968 and clinical marketing in the
USA in 1973 [116], SSD has been frequently documented
as a cause of leukopenia and lowered granulocyte counts,
but these changes have normalised when therapy has been
discontinued. Thus, Thomson et al. [117] recorded reduced
white blood cell counts (WBC) of ≤5000/mm3 in burn-
wound patients treated with either SSD or silver nitrate
w i t h i n3d a y so fi n j u r y( 4 0o f8 4a f t e rS S Da n d1 3o f
30 following silver nitrate therapy). Choban and Marshall
conﬁrmed this risk in patients with 15% total body surface
burn wounds, but demonstrated that WBC normalised
when SSD or silver nitrate therapy was withdrawn with
no further complications [118]. In their view, SSD-induced
leukopeniashouldbeviewedasa“self-limitingphenomenon
that does not increase the incidence of infectious compli-
cations nor aﬀect the ﬁnal outcome”. Nevertheless, burn-
wound strategies should predict that where WBC fall to
less than 2000/mm−3, SSD therapy be terminated as a
precaution [119]. The mechanism for postburn leukopenia
is imperfectly understood. Whilst in vitro and experimental
studies in mice indicate that SSD can suppress leukocyte
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situation SSD may be just one contributory factor. Burn
stress or silver allergy may be partly responsible [121–123].
Leukopenia/neutropenia was reported in nine patients with
a mean WBC of 2,680/mm3 where SSD was associated
with immature band forms in peripheral blood, but WBC
normalised within 2-3 days [124]. Prospectively, a survey of
opinion in 101 burn clinics in North America and review of
published case reports indicated that postburn leukopenias
attributable to SSD, silver nitrate, or other causes “hold little
risk for the burn patient” [119].
Methaemaglobinaemia is a supposedly rare complication
of 0.5% silver nitrate therapy in burn clinics, particularly in
children [125]. The condition is attributable to alterations
in the oxygen-carrying capacity of haemoglobin resulting
from oxidation of ferrous iron (Fe++) to the ferric state
(Fe+++) through the action of the nitrate anion [126], and
not through Ag+ absorption. Nitrate is reduced to nitrite by
nitrate reductase activity of intestinal ﬂora as a preliminary
to methaemoglobin formation. The condition may be life
threatening, but normal blood oxygenation is restored with
intravenous therapy with methylene blue [127].
3.4. Silver in Bone. Bone toxicity is not widely recognised in
the safety evaluation of silver and silver-containing products,
but there are strong indications from in vitro models
that Ag+ interacts with and binds to the hydroxyapatite
complex and can displace calcium and magnesium ions
[128, 129]. Other research has demonstrated that Ag+
induces calcium release from the sarcoplasmic reticulum
in skeletal muscle by acting on the calcium-release chan-
nels and calcium-pump mechanisms, presumably through
oxidising sulphydryl groups [130]. Although this suggests
that bone and possibly cartilage are vulnerable to prolonged
release of Ag+ used as an antibiotic in bone cements,
orthopaedic pins, dental devices, and so forth, this has
not been established so far. No cases of osteoporosis have
been reported following long-term ingestion or inhalation
of silver or -implantation of silver-coated or impregnated
orthopaedic devices. Osteoblasts cultured in the presence of
silver wire failed to show a statistically signiﬁcant reduction
in cell growth after 48 hours, although alkaline phosphatase
activity was markedly depressed [131]. Silver salts of varying
solubility—oxide, chloride, sulphate, or phosphate—were
entirely biocompatible with osteogenesis in cultured rabbit
bone, and foreign body reactions were minimal [132]. With
the exception of the oxide, all seemed to maintain the
compressive strength of rabbit bone, following implantation
in paraspinal muscles (Silver-coated orthopaedic ﬁxing pins
designed for external ﬁxation were entirely compatible with
bony and periosseous tissues [133]. In a clinical situation,
inappropriate use of a silver-impregnated bone cement led
to a 1000-fold increase in argyraemia and silver in acetabular
cavity of 103.3μg·L−1, but these high systemic and local
silver concentrations were not associated with osteological
damage in this patient [66, 67].
3.5. Contact Allergy and Delayed Hypersensitivity. Metal
allergiespresentmajorproblemsindiagnosisindermatology
clinics since most metals and metal salts are impure and
contaminated by other metals like nickel, chromium, and
cobalt with recognised risk [134, 135]. Allergy to silver is a
knownadverseeﬀectofsilverexposureincoinage,cosmetics,
and in patients treated with silver nitrate, SSD, and sustained
silver-release wound dressings to control wound infections,
but a proportion of predisposed metal workers, jewellers,
photographers, and other persons exposed to silver or silver
salts occupationally may exhibit symptoms of delayed con-
tact hypersensitivity [134]. The true extent of the problem is
not known as diagnostic standard patch tests using 2% aq.
silver nitrate are not routinely conducted except in health
threatening situations.
Argyria or overt skin reactions do not arise through
contact with metallic silver, but small amounts of Ag+
released in the presence of skin exudates or moisture
are suﬃcient to evoke symptoms of contact sensitivity in
predisposed persons [134]. Aged solutions of silver nitrate
with greater ionisation were shown to be appreciably more
allergenic than freshly prepared reagents [136]. Although
argyria as a response to silver and colloidal silver preparation
had been reported from the beginning of the 20th Century
[137, 138], the ﬁrst reported case of true allergy was seen in a
26-year-old man following use of colloidal silver (Argyrol) to
treatasthmaandhayfever[139].Silverallergywasconﬁrmed
usingscratchtestsandintradermalinjectionof0.05mlof1%
silver nitrate. In more recent times, contact allergies to Ag+
have been conﬁrmed in occupational situations, and such
conditions as “silver-workers ﬁnger”, “silver-fulminate itch”
(in explosives industry), and “silver coat dermatitis” have
been recognised [140–142]. Numerous cases are reported
of SSD-related allergic dermatoses, with conﬁrmation using
patch and photopatch testing [143, 144].
4.In Vitro Cytogenicity,Mutagenicity,and
Carcinogenicity
Cell culture systems have been developed in recent years as
inexpensive means of examining intracellular metabolism of
xenobiotic materials and mechanisms of cellular toxicity. In
vitro tests have limited value in relation to in vivo assays
discussed above for concentrations exceeding 5ppm, and as
far as I am aware, full preliminary screening for mutagenicity
and carcinogenicity for silver and silver compounds has
not been completed [145]. Published cytotoxicity tests and
in vivo experience indicate unequivocally that silver is
not carcinogenic in any tissue and should be placed in
a“ N oR i s k ”c a t e g o r y[ 146]. A large number of in vitro
toxicity studies demonstrating the cytotoxic eﬀects of metal-
lic silver, silver sulphadiazine, or other silver compounds
have been published in recent years, but observations in
cultured ﬁbroblasts, keratinocytes, and other human cell
lines reﬂect the ability of Ag+ t or e a c tw i t hs u l p h y d r y l
groups, other protein residues, and enzymes associated with
cell membranes leading to denaturation, structural damage,
and mitochondrial dysfunction, in much the same way
to that seen in bacterial and fungal cells [1]. Fibroblasts
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silver toxicity in cultured cells may be inﬂuenced by the
age of the donor and the composition of the culture
medium [147]. Human diploid ﬁbroblasts and fresh human
donor dermal ﬁbroblasts were inhibited by short-term
exposure to silver sulphadiazine and impaired proliferation
was associated with marked changes in cell morphology
including cytoplasmic deterioration and degeneration of
nuclei and cell organelles [148]. Growth factors including
platelet-derived growth factor (PDGF), epidermal growth
factor (EGF), and basic ﬁbroblast growth factor (β-FGF)
which modulate cell proliferation, migration, and functional
maturation in epidermal repair following injury have been
shown to cytoprotect dermal ﬁbroblasts from injury by
silver sulphadiazine, suggesting that cells activated by growth
factors are more resistant to the toxic eﬀects of silver
antibiotic [14], but this is unconﬁrmed by clinical or in vivo
studies.
5. ReproductiveToxicityand Teratogenicity
Insuﬃcient evidence is available presently to show that
administration of silver or ionisable silver compounds in
pregnancy is a cause of infertility, impaired foetal growth,
or abnormal development in any species. Silver nitrate (1%)
administered by intrauterine injection to 13 cynomolgus
monkeys between 27 and 43 days of pregnancy caused early
vaginal bleeding and termination of pregnancy but two of
sevenanimalsre-matedbecamepregnantagainanddelivered
healthy oﬀspring [149]. It is not known whether Ag+ passes
transplacentally to accumulate in the foetus.
6.Nanotechnology andNanocrystallineSilver
The antibacterial and antifungal eﬃcacy of silver in medical
devices, clothing, wound dressings, and so forth is directly
proportional to the release of Ag+ and its availability
to interact with cell membranes leading to lethality and
inactivation of toxins produced [4]. Burrell has clearly
identiﬁed the ionizing properties of metallic silver and
silver compounds and shown that nanocrystalline particles
(<20mn diameter) exhibit a solubility of 70–100μg·mL−1,
that is, up to 100-fold greater than metallic silver. He
is of the opinion that these nanoparticles show speciﬁc
physical and chemical properties which may inﬂuence
their biological action. In his view, the “grain boundary
region of crystals of <20nm may represent a new state
of solid matter” [4]. Diﬀerences in biological eﬀect are
illustrated in the antibacterial eﬀects against Pseudomonas
aeruginosa in culture and in the anti-inﬂammatory action
of microcrystalline silver and silver nitrate in rodent
models discussed above. Wound care products containing
nanocrystalline silver (e.g., Acticoat, Smith & Nephew)
have an acclaimed success in controlling infections in
chronic wounds and ulcers [26]. However, further studies
are necessary to determine whether the antibacterial and
physiological eﬀects are attributable to the silver ion per
se or to the unique biological properties of the silver
microcrystals.
Workers involved in production of nanocrystalline silver
over an extended period are potentially at risk of inhal-
ing microparticles leading to argyria and argyrosis unless
stringent safety precautions (air ﬁlters, personal respirators,
etc.) are followed [4]. Workers may be exposed to silver
in the workplace unintentionally through hand to mouth
transfer of materials or swallowing particles cleared from the
respiratory tract. The National Institute of Safety and Health
(NIOSH) is currently conducting research to determine
the extent to which nanocrystalline silver poses a threat
to exposed workers and under what circumstances and
emphasising that presently no international standards have
been introduced in the USA or elsewhere [150].
Speciﬁc toxicity studies and clinical trials have been
conducted in relation to wound dressings including Acti-
coat containing nanocrystalline silver, where burn-wound
patients exposed for up to 9 days exhibited increases in
blood silver (56.8μg·L−1), which normalised to 0.8μg·L−1
after 6 months [151]. Clinical studies are urgently required
to examine the occupational risks associated with the use
of highly dispersed nanocrystalline silver in general-purpose
biocides, consumer products, electronics, metallurgy, and
chemical catalysis [152, 153].
Laboratory evaluations of the toxicity of nanocrystalline
silver are not numerous. Some have been discussed above
in relation to the cytotoxicity and genotoxicity of silver
particles in cultured lung ﬁbroblasts and glioblastoma cells
[154]. Silver is absorbed into cultured cells by a pinocytic
mechanism, and as in bacteria and fungi, can be expected to
interact with and precipitate with cytoplasmic proteins lead-
ing to cell death. Minimal cytotoxic concentrations reﬂect
the subcellular proteins and Ag+-binding sites. Cultured
cells exposed to silver particles at 6.25–50μg·mL−1 showed
alteredcellshapeandshowedevidenceofoxidativestressand
increasedlipidperoxidation[155].Inhalationtoxicitystudies
in rats conducted for Samsung Electronics Co. (Korea) have
shown that the lungs and liver are principle target organs but
that no eﬀects were observable at environmental concentra-
tions of 100mg/m3 [58, 59, 156]. Exposures at 133mg/m3
or 515mg/m3 evoked inﬂammatory and granulomatous
changes in the lung and bile duct hyperplasia.
7. Discussion
The present paper emphasises that health risks associated
with systemic absorption of silver as Ag+ are low. Argyria
and argyrosis are the principle observable changes associated
with long-term exposure to ingestion or inhalation of
metallic silver or ionisable silver compounds, but neither is
life threatening or associated with irreversible tissue damage.
It is debatable therefore whether these conditions should be
classiﬁed as “toxic changes’’, but it should be emphasised
that severe long-lasting argyria and argyroses arising from
unprotected occupational exposures to silver or unregulated
consumption or inhalation of unregulated colloidal silver
preparations can be profoundly disﬁguring and a cause of
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be dismissed as irrelevant observations [18, 19, 38, 157, 158].
Ihaveseennounequivocalevidencetoshowthatsilverexerts
morphological damage on neurological tissues [72, 73].
Clinical experience has shown that transitory changes
in hepatic and renal enzyme systems in patients exposed to
high clinical or environmental silver are of minimal toxic
signiﬁcance [17, 33, 65]. At the moment, there is no good
evidence to show that silver accumulates preferentially in
bone, inﬂuences signiﬁcantly calcium-modulated events in
the heart, skin, and other tissues, or is a putative cause of
osteoporosis, but further clinical research is required. On
the other hand, there is irrefutable evidence that silver like
most other xenobiotic metals, can evoke delayed contact
hypersensitivity reactions and allergy in predisposed persons
and this should be viewed as potential toxic hazard, albeit
thatthe extent ofthe risk is not known [134].Animalmodels
have provided little guidance as to potential risks associated
with silver exposure or sensitivity to argyria in humans,
but some have provided useful information on cellular
management of the metal and the role of silver-binding and
carrier proteins in cytoprotection and metabolism [1, 14,
31, 71, 72]. In vitro toxicity studies with silver exposed to
ﬁbroblasts, keratinocytes, or other cell lines have minimal
relationship to in vivo experiments using recognised animal
models, but they are useful in conﬁrming the lack of
mutagenicity or carcinogenic change attributable to silver.
Regulatory authorities have evaluated reference stan-
dards and exposure limits to metallic silver and soluble
silvercompoundsinoccupationalhealthsituations,drinking
water, medical devices, wound dressings, and consumer
productsbasedonpublisheddataonargyriaand/orargyrosis
as the only tangible evidence of silver exposure [2, 3, 44, 100,
146, 150]. At the moment, there are no clear guidelines from
case studies or occupational health reports to indicate a clear
relationship between clinical or occupational exposure to sil-
ver,bloodsilverlevels,orminimalbodysilverconcentrations
consistent with early signs of the condition. As East et al.
[39] showed in only one patient, profound argyria resulting
from 2 years exposure to silver acetate antismoking device
was associated with total body accumulation of 6.4g of
silver, much of which was deposited in the skin 71.7μg·g−1.
Althoughdermalsilverconcentrationswere8000-foldhigher
than normal reference values [159], the patient remained
in apparent good health. Elsewhere, argyria in a burn
patienttreatedwithasustainedsilver-releasewounddressing
was associated with blood silver levels of 107μg·kg−1 and
urinary silver of 28μg·kg−1, but no other changes [98].
Other studies claim that total body silver concentrations
of 4-5g can produce the clinical picture of argyria [160].
Fung and Bowen noted that in reported cases up to 1973,
365 cases of argyria had been referred to the US Food
and Drug Administration and that a total body burden of
3.8g elemental silver was required to evoke argyria [18].
It is emphasised that estimations of tissue and body silver
in these older studies are considerably less accurate than
those available these days using ﬂameless thermal atomic
absorption spectrophotometry or mass spectrometry with
sensitivity of 1μg·L−1 tissue silver measurement or lower (B.
Sampson, personal communication) [36].
Opportunities these days to study silver intake as a
cause of detectable argyric change are few, since silver
compounds are not legally available for oral or enteric
administration (other than silver acetate in antismoking
devices) in many countries, and introduction of far-reaching
international health and safety standards at work regulations
greatly reduces the risk of chronic occupational exposure.
Currentexposurelimitsformetallicsilverandionisablesilver
compounds of 0.01mg/m3 in air (silver levels in drinking
water 0.10mg·L−1) set by the National Institute for Occu-
pational Safety and Health and the American Conference
on Governmental Industrial Hygienists in environmental
exposures and drinking water regulations of <0.10mg.
Ag·L−1 (EPA) indicates that humans are unlikely to be
exposed to suﬃcient silver in their food, drinking water,
workplace, or in therapeutics in their lifetime to provoke
symptoms of argyria [2, 3, 44, 161]. The amount of Ag+
released from catheters, textiles, and wound dressings using
silver for permitted antibiotic purposes is very low and
probably of no toxicological signiﬁcance, other than being a
cause of allergy [1, 61]. However, indiscriminate ingestion or
inhalation of colloidal silver preparations (with unspeciﬁed
concentrations of ionisable silver) for infective and non-
infective conditions still presents a real risk for argyria and
argyrosis and associated psychological problems [162, 163].
Older studies frequently cited in calculating reference values
for silver such as those conducted by Gaul and Staud [138]
and Hill and Pillsbury [137]s h o u l db ev i e w e dw i t hc a u t i o n .
The former discussed incidences of argyria in a total of
70 patients exposed intravenously to varying doses of the
highly toxic antisyphilitic drug silver arsphenamine (for
which the chemical formula and ionisation potential are still
not resolved) and undisclosed colloidal silver preparations
claimed that argyria developed after a total dose equivalent
to 1.84g of silver. Since the actual formulation of colloidal
silver products available these days is not known, it is even
lesslikelythatthesilvercontentofthoseavailablein1935was
known. Hill and Pillsbury gave a lucid account of the clinical
picture of argyria [137], but lacked the facility to examine
fully the implications of silver exposure and the pathological
features of the condition.
Silver should not be regarded as a cumulative poison
[73]. Only in cases of chronic systemic silver overload
situations where excretory mechanisms become saturated,
does silver deposit in an inert fashion in lysosomal or
intercellular sites, unrelated to tissue damage. In these
situations, selenium serves as a major protective factor in
precipitating the silver in a highly insoluble and hence inert
form of silver selenide. Although some of this may be taken
up in lysosomes in macrophages, the deposits are essentially
long lived or permanent. Available knowledge indicates that
innormalhealthypeople,argyraemiasof<3μg·L−1 areusual
[36], and that raised levels are seen in persons occupationally
exposed to the metal without suitable protective measures
(face masks, etc.) [17, 33, 34, 53]. The inherent human risks
of argyria through entering food chains presenting health
risks to people living in areas highly polluted with silver
residues from factory wastes as in the San Fransisco Bay
region require urgent attention [164].12 Advances in Pharmacological Sciences
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